Zalutumumab

Drug Profile

Zalutumumab

Alternative Names: HuMax-EGFr

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Genmab
  • Developer Danish Head and Neck Cancer Group; Genmab
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Dimerisation inhibitors; Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Head and neck cancer
  • Discontinued Colorectal cancer; Non-small cell lung cancer

Most Recent Events

  • 22 Sep 2011 Genmab completes a phase III trial in Head and Neck cancer in Brazil, Canada, Russia, and EU (NCT00382031)
  • 24 Jun 2011 Suspended - Phase-II for Head and neck cancer in USA (IV)
  • 24 Jun 2011 Suspended - Phase-III for Head and neck cancer in Belgium (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top